Get the Stockscreener App
12.78
2.49%
0.31
Pre-market:
13.99
1.21
+9.47%
Celcuity Inc stock is traded at $12.78, with a volume of 256.55K.
It is up +2.49% in the last 24 hours and down -19.27% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$12.47
Open:
$12.43
24h Volume:
256.55K
Relative Volume:
0.95
Market Cap:
$463.01M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-4.8226
EPS:
-2.65
Net Cash Flow:
$-53.91M
1W Performance:
-12.70%
1M Performance:
-19.27%
6M Performance:
-23.93%
1Y Performance:
-2.29%
1-Day Range:
$12.07
$13.00
1-Week Range:
$11.51
$15.22
52-Week Range:
$11.51
$22.19
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CELC | 12.78 | 463.01M | 0 | -63.78M | -53.91M | -2.65 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Celcuity’s (CELC) “Buy” Rating Reiterated at HC Wainwright - Defense World
Celcuity (NASDAQ:CELC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Celcuity stock hits 52-week low at $12.14 amid market shifts - Investing.com
500: Something went wrong - Investing.com India
Celcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Q3 2024 Earnings Call Transcript - Insider Monkey
COMMODORE CAPITAL LP's Strategic Acquisition of Celcuity Inc Sha - GuruFocus.com
Celcuity Inc. Reports Q3 Progress and Financials - TipRanks
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update - The Manila Times
Celcuity Inc (CELC) Quarterly 10-Q Report - Quartz
Celcuity CEO to Present at Stifel and Jefferies Healthcare Conferences This Month | CELC Stock News - StockTitan
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences - GlobeNewswire
Long Term Trading Analysis for (CELC) - Stock Traders Daily
Celcuity (CELC) Scheduled to Post Earnings on Thursday - MarketBeat
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call - GlobeNewswire
Celcuity (CELC) to Report Q3 2024 Earnings: Oncology Pipeline Update Coming | CELC Stock News - StockTitan
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts (NASDAQ:CELC) - Seeking Alpha
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Analysts Set Celcuity Inc. (NASDAQ:CELC) PT at $29.17 - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 9.3% in October - MarketBeat
Asml Holdings NY Reg ADR (ASML-Q) QuotePress Release - The Globe and Mail
Celcuity director Buller sells $5,687 in stock - Investing.com India
Celcuity director Buller sells $5,687 in stock By Investing.com - Investing.com Australia
Objective long/short (CELC) Report - Stock Traders Daily
Short Interest in Celcuity Inc. (NASDAQ:CELC) Rises By 26.7% - MarketBeat
Celcuity Inc. expands share authorization to 95 million By Investing.com - Investing.com Australia
Celcuity Inc. expands share authorization to 95 million - Investing.com India
Celcuity (NASDAQ:CELC) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Celcuity (NASDAQ:CELC) Stock Price Down 4.5%Here's What Happened - MarketBeat
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings - GuruFocus.com
Stifel raises Celcuity stock price target, maintains buy on sales potential - Investing.com
Celcuity (NASDAQ:CELC) PT Raised to $42.00 at Stifel Nicolaus - MarketBeat
Brokerages Set Celcuity Inc. (NASDAQ:CELC) PT at $28.67 - MarketBeat
Point72 Asset Management L.P. Buys New Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Driehaus Capital Management LLC Purchases 78,525 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September - MarketBeat
(CELC) Investment Report - Stock Traders Daily
Blue Owl Capital Holdings LP Takes $1.07 Million Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Samlyn Capital LLC Purchases 637,190 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Samlyn Capital LLC - MarketBeat
It is Poised to be a Bull Market for Celcuity Inc (CELC) - SETE News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Ratios Revealed: Decoding Celcuity Inc (CELC)’s Financial Health - The Dwinnex
Celcuity (NASDAQ:CELC) Sees Large Volume Increase - MarketBeat
Celcuity (NASDAQ:CELC) Shares Down 3.5% - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Celcuity (CELC) Holds a Potential Game-changer in Cancer Treatment - Nasdaq
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):